Advanced Enzyme Technologies Limited continued its approved open market buyback by repurchasing 63,718 equity shares on August 31, 2026. The transactions were executed exclusively on the National Stock Exchange (NSE) at an average acquisition price of ₹297.65, well below the maximum permitted price of ₹500 per share.

Buyback Progress Update

Emkay Global Financial Services Limited, acting as the Manager to the Buyback, facilitated the transactions. As of August 31, 2026, the cumulative number of equity shares bought back stands at 8,25,028. There were no closed-out quantities reported for the day or previously. This progress moves the company closer to its initial deployment target of ₹278,800,000, which must be utilized within the first half of the offer period.

Buyback Offer Parameters

The buyback targets up to 1,394,000 equity shares, constituting approximately 1.24% of the total paid-up equity share capital as of August 8, 2026. The maximum buyback size is ₹697,000,000, funded entirely from free reserves and internal accruals with no borrowed funds utilized.

The company is required to utilize at least 75% of the Maximum Buyback Size, i.e., ₹522,750,000. Furthermore, at least 40% of the Buyback Size, i.e., ₹278,800,000, must be deployed within the initial half of the Offer Period. The buyback offer is expected to open on or before August 14, 2026, and close no later than November 20, 2026, being sixty-six Working Days from the opening date.

Premium and Market Context

The Maximum Buyback Price of ₹500 carries a substantial premium over recent market benchmarks. On August 8, 2026, the closing market price was ₹324.40 on BSE and ₹324.35 on NSE.

This premium reflects management’s confidence in the intrinsic value of the shares and serves as a strong signal to investors regarding the company’s financial health and future prospects.

Capital Structure Impact

If the full Maximum Buyback Size is utilized at the Maximum Buyback Price, the issued, subscribed, and paid-up capital will reduce from 111,976,150 shares to 110,582,150 shares. Promoters and persons in control are excluded from participating in the buyback; their shares will remain frozen at the ISIN level from August 8, 2026, until the buyback closes.

Financial Health and Rationale

The buyback is underpinned by strong financial performance. For Q1 FY27 (ended June 30, 2026), the company reported Revenue from Operations of ₹1,158.57 million and Profit After Tax of ₹223.46 million. In FY2026, Revenue from Operations stood at ₹4,527.66 million with a PAT of ₹1,318.06 million.

The Board confirmed that the company has no subsisting defaults in repayment of deposits, debentures, preference shares, dividends, or term loans. A cash escrow of ₹174,250,000 (25% of Maximum Buyback Size) has been deposited with HDFC Bank Limited. Emkay Global Financial Services Limited serves as the Manager to the Buyback, while MUFG Intime India Private Limited is the Registrar. The process complies with Regulation 5(vii) of the SEBI (Buy-back of Securities) Regulations, 2018, and relevant provisions of the Companies Act, 2013.

Advanced Enzyme Technologies Limited has uploaded the full transcript of the conference call held with analysts and investors to discuss its unaudited financial results for the quarter ended June 30, 2026 (Q1FY27). The call took place on Wednesday, August 12, 2026, and was moderated by Akash from Door Sabha. The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Context

During the quarter, Advanced Enzyme Technologies reported a consolidated net profit of ₹386 million, a 5% decline from ₹404 million in Q1FY26. Revenue from operations grew by 2% to ₹1,898 million. However, EBITDA fell 10% year-on-year to ₹510 million, compressing the EBITDA margin to 27% from 30%. This margin pressure was driven by declines in the Human and Animal Nutrition segments, despite growth in Bio-Processing and Specialized Manufacturing.

Management Commentary

Mukund Kabra, Whole-time Director, attributed the muted start to the fiscal year to global geopolitical tensions and supply chain disruptions, which impacted energy and raw material pricing. He highlighted that the top-line growth of 2% was impacted by an additional sales reversal of ₹100 million due to revenue recognition principles regarding goods in transit. Without this reversal, revenue would have been approximately ₹1,998 million, representing roughly 8% growth over the prior year's base.

Kabba noted that while the Human Healthcare segment saw a 7% YoY decline in revenue to ₹1,139 million, the Bioprocessing segment delivered strong 30% YoY growth to ₹306 million, driven by the food business. Specialized Manufacturing also posted robust 41% YoY growth to ₹200 million.

Beni Rauka, Group Chief Financial Officer, elaborated on the cost structure, noting that elevated power and fuel costs contributed to the margin contraction. He stated that consolidated debt stands at about 20% of revenue, down from 22% in Q1FY26. Rauka also provided subsidiary performance details: JC Biotech reported revenue of ₹195 million and PAT of ₹10 million, while Evoxx reported revenue of ₹74 million but incurred a negative PAT of ₹18 million. SciTech, another subsidiary, saw its revenue rise to ₹201 million with a PAT of ₹13 million, compared to a loss in the prior year.

Strategic Updates

The Board has approved a buyback of ₹697 million at a ceiling price of ₹500 per share via the open market route. Additionally, the company announced the acquisition of the remaining 4.28% stake in JC Biotech for ₹79.79 million, making it a wholly-owned subsidiary.

Regarding capital expenditure, Rauka confirmed an outlay of ₹123 crore for FY27, with approximately ₹50 crore allocated to R&D and the remainder for growth initiatives. He noted that fermentation utilization is close to 70-75%, necessitating capacity expansion plans.

US Market Challenges

Management addressed questions regarding the sluggish growth in the US market. Rauka explained that the business is undergoing a strategic shift towards branding products rather than selling unbranded ingredients, a process taking time to consolidate. Geopolitical issues and logistical challenges have further complicated operations. The company expects steady-state growth of 8-10% in the US business once these transitions stabilize.

Next Steps

The audio recording of the conference call was previously uploaded on August 12, 2026. The transcript is now available on the company’s investor relations page. The information was filed with both BSE Limited and the National Stock Exchange of India Ltd.

What the Numbers Show

The divergence between revenue growth (2%) and profit decline (5%) highlights the impact of both operational inefficiencies and one-off accounting adjustments. The ₹100 million sales reversal alone accounts for a significant portion of the missed revenue potential, suggesting that underlying demand may be stronger than the headline figure indicates. However, the compression in EBITDA margins from 30% to 27% signals persistent cost pressures from energy inputs that could weigh on profitability even as volumes recover.